2d
GlobalData on MSNVivani treats first patient with long-lasting drug implant for weight lossA day after announcing a business split-off to focus on weight loss and diabetes implants, Vivani Medical has implanted the ...
Vivani Medical completed enrollment in its LIBERATE-1 trial, testing a six-month GLP-1 implant for weight management.
Hosted on MSN1mon
Study Finds Exenatide Not Beneficial for Parkinson DiseaseFRIDAY, Feb. 7, 2025 (HealthDay News) -- The glucagon-like peptide-1 receptor agonist exenatide does not yield ... exenatide 2 mg by subcutaneous pen injection once per week over 96 weeks or ...
Hosted on MSN1mon
Diabetes drug similar to Ozempic showed no benefits for patients with Parkinson’s diseaseHalf of the participants received a weekly injection of two milligrams of the drug exenatide, which is a GLP-1 receptor agonist similar to medicines such as Ozempic or Wegovy. The other half of ...
Objective: This study evaluated the ability of the incretin mimetic exenatide (exendin-4) to improve glycemic control in patients with type 2 diabetes failing maximally effective doses of a ...
The GLP-1 drug, exenatide, has no positive impact on the movement, symptoms or brain imaging of people with Parkinson’s, ...
Bydureon (exenatide), a weekly type 2 diabetes GLP-1 class injection, is nearing the end of its patent life and is also under threat from Novo Nordisk’s next-generation weekly jab, semaglutide.
AstraZeneca announced that the EC green-lighted the new formulation of the once-weekly type-2 diabetes injection, which will be marketed as Bydureon BCise (exenatide 2mg prolonged-release suspension).
Objective–To investigate the effect of treatment with the glucagon-like peptide 1 receptor agonist exenatide on weight loss and metabolic parameters in obese nondiabetic women. Research Design ...
In fact, manufacturers of marketed, weekly injectable GLP-1 products recommend ... to support the potential application of this GLP-1 (exenatide) implant in the treatment of type 2 diabetes ...
Findings showed MDS-UPDRS OFF medication scores had worsened (increased) by 5.7 points in exenatide-treated patients compared with a 4.5 point increase with placebo. Treatment with once-weekly ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results